Ashland Inc. (ASH) Analyst/Investor Day Transcript
Ashland is using cost savings, portfolio optimization and buybacks to strengthen margins and free cash flow despite tariff and demand headwinds.
Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.
Ashland NYSE: ASH reported higher sales across all four business units in its fiscal third quarter of 2026, supported by volume growth, pricing actions and demand in its Life Sciences and Personal Care operations. The company reaffirmed its full-year sales and adjusted EBITDA outlook, while lowering its adjusted earnings-per-share growth forecast because of a higher tax rate tied to unfavorable discrete items.
ASH's Q3 sales beat estimates as volume growth lifted all segments, but adjusted earnings missed and the company lowered its fiscal 2026 EPS growth outlook.
Ashland (ASH) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.04 per share a year ago.
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ashland (ASH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ashland (ASH) reported earnings 30 days ago. What's next for the stock?
ASH posts weaker Q2 results with earnings and sales missing estimates despite gains in Personal Care and steady Life Sciences demand.
Ashland Inc. (ASH) Q2 2026 Earnings Call Transcript